Soiken Holdings Inc. (TYO:2385)
208.00
-2.00 (-0.95%)
Nov 18, 2026, 10:23 AM JST
Soiken Holdings Revenue
Soiken Holdings had revenue of 785.00M JPY in the quarter ending September 30, 2026, a decrease of -44.52%. This brings the company's total for the last twelve months to 3.24B, down -33.46% year-over-year. In the fiscal year ending June 30, 2026, Soiken Holdings had annual revenue of 3.87B, down -20.15%. That makes Soiken Holdings the 33,810th largest company in the world by revenue and 3,488th in Japan.
Revenue (ttm)
3.24B
Revenue Growth
-33.46%
P/S Ratio
1.69
Revenue / Employee
72.02M
Employees
45
Market Cap
5.44B
Revenue by Segment
Fiscal year ended Jun 30, 2026 See the full Soiken Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.87B | -977.00M | -20.15% |
| Jun 30, 2025 | 4.85B | -310.00M | -6.01% |
| Jun 30, 2024 | 5.16B | -2.92B | -36.16% |
| Jun 30, 2023 | 8.08B | -1.27B | -13.57% |
| Jun 30, 2022 | 9.35B | 405.00M | 4.53% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CellSource | 3.67B |
| MEDINET | 998.00M |
| OncoTherapy Science | 712.00M |
| Chiome Bioscience | 615.15M |
| Kringle Pharma | 342.21M |
| Cyfuse Biomedical K.K. | 305.00M |
| Nano Holdings | 202.00M |
| BrightPath Biotherapeutics | 84.00K |